Skip Navigation

Briefings in Functional Genomics 2002 1(3):305-315; doi:10.1093/bfgp/1.3.305
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Charboneau, L.
Right arrow Articles by Paweletz, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charboneau, L.
Right arrow Articles by Paweletz, C. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Henry Stewart Publications

Technique review

Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays

Lu Charboneau
Manager of the Laser Capture Microdissection Core Facility at NIH and working with the National Cancer Institute (NCI) in the Laboratory of Pathology.

Heather Scott and Tina Chen
Laboratory Technicians, Laboratory of Pathology, NCI.

Mary Winters
Obtained her BSc in Medical Technology from the Ohio State University in 1988 and is currently working in the Laboratory of Pathology at the NCI.

Emanuel F. Petricoin, III
Co-Director of the NCIFDA Clinical Proteomics Program and Senior Investigator at the Center for Biologics Evaluation and Research at the FDA.

Lance A. Liotta
Co-Director of the NCI-FDA Clinical Proteomics Program and Chief of Laboratory for the Laboratory of Pathology at the NCI.

Cloud P. Paweletz
Obtained his PhD in Chemistry from Georgetown University and is currently a post doc in the Laboratory of Pathology at the NCI.


Cloud P. Paweletz, National Cancer Institute—Food and Drug Administration, Clinical Proteomics Program, Building 29A, Room 2B02, Bethesda, MD 20892, USA Tel: +1 301 827 1754 Fax: +1 301 480 3256 E-mail: paweletz{at}cber.fda.gov

Protein microarrays offer a new means by which to conduct quantitative profiling of disease-associated proteins. The knowledge gained may provide novel strategies for early detection, diagnosis and therapeutic intervention. A variety of sophisticated approaches, including gene arrays, sequencing consortiums and large-scale two-dimensional gel electrophoresis, continue to generate lists of proteins potentially linked to disease aetiology and progression. The challenge is to evaluate quantitatively promising lead protein candidates using matched normal and diseased cell populations. In contrast to the antibody array, the reverse phase protein microarrays (RPPA) do not require labelling of cellular protein lysates, and constitute a sensitive high throughput platform for marker screening, pathophysiology investigation and therapeutic monitoring. In this paper, examples will be provided using RPPAs in the study of the apoptotic signalling cascade and in the evaluation of the expression of organ-specific protein makers using microdissected human organ cell lysates configured as ‘human body arrays’.

Keywords: protein microarrays, proteomics, laser capture microdissection, clinical proteomics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BioinformaticsHome page
E. S. Neeley, S. M. Kornblau, K. R. Coombes, and K. A. Baggerly
Variable slope normalization of reverse phase protein arrays
Bioinformatics, June 1, 2009; 25(11): 1384 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
L. Zhang, Q. Wei, L. Mao, W. Liu, G. B. Mills, and K. Coombes
Serial dilution curve: a new method for analysis of reverse phase protein array data
Bioinformatics, March 1, 2009; 25(5): 650 - 654.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Kornblau, R. Tibes, Y. H. Qiu, W. Chen, H. M. Kantarjian, M. Andreeff, K. R. Coombes, and G. B. Mills
Functional proteomic profiling of AML predicts response and survival
Blood, January 1, 2009; 113(1): 154 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. T. Hennessy, Y. Lu, E. Poradosu, Q. Yu, S. Yu, H. Hall, M. S. Carey, M. Ravoori, A. M. Gonzalez-Angulo, R. Birch, et al.
Pharmacodynamic Markers of Perifosine Efficacy
Clin. Cancer Res., December 15, 2007; 13(24): 7421 - 7431.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. M. Hurt, S. B. Thomas, B. Peng, and W. L. Farrar
Integrated molecular profiling of SOD2 expression in multiple myeloma
Blood, May 1, 2007; 109(9): 3953 - 3962.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Tibes, Y. Qiu, Y. Lu, B. Hennessy, M. Andreeff, G. B. Mills, and S. M. Kornblau
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.
Mol. Cancer Ther., October 1, 2006; 5(10): 2512 - 2521.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. M. Sheehan, V. S. Calvert, E. W. Kay, Y. Lu, D. Fishman, V. Espina, J. Aquino, R. Speer, R. Araujo, G. B. Mills, et al.
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
Mol. Cell. Proteomics, April 1, 2005; 4(4): 346 - 355.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.